Blue Barn Wealth LLC Trims Position in Haleon plc (NYSE:HLN)

Blue Barn Wealth LLC lessened its stake in Haleon plc (NYSE:HLN) by 33.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,390 shares of the company’s stock after selling 5,152 shares during the quarter. Blue Barn Wealth LLC’s holdings in Haleon were worth $99,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sierra Ocean LLC purchased a new stake in shares of Haleon during the 4th quarter valued at about $26,000. Versant Capital Management Inc boosted its holdings in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Haleon during the fourth quarter worth about $35,000. Toronto Dominion Bank lifted its holdings in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in shares of Haleon during the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on HLN. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday. Finally, Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

Haleon stock opened at $10.55 on Thursday. The firm has a market capitalization of $47.74 billion, a P/E ratio of 31.01, a PEG ratio of 2.82 and a beta of 0.28. The business has a 50-day moving average of $9.63 and a 200-day moving average of $9.85. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. On average, equities analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.